Indeed, despite the growing interest that this complex target recently attracts due to its oncogenic role in mediating many DDR pathways on which cancer cells rely when canonical ones are impaired, there are no FDA-approved RAD52 inhibitors on the market, and no RAD52 inhibitors are reported to be in clinical development yet (ClinicalTrials.gov)22. Here, RAD52 is linked to cancer.